Sharon D. Solomon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sharon D. Solomon has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Barbara S Hawkins
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
2 shared publications- Aaron Carass
Johns Hopkins University
1 shared publication Adam S Wenick
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
1 shared publication- Andrew Lang
Department of Electrical and Computer Engineering, The Johns Hopkins University, Baltimore, MD 21218, USA
1 shared publication - Angeline M. Nguyen
Wilmer Eye Institute, Johns Hopkins University, 600 North Wolfe Street, Maumenee B-110, Baltimore, MD, 21287, USA.
1 shared publication Ann Margret Ervin
School of Medicine, Johns Hopkins University, Baltimore, Maryland; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland
1 shared publication
Latest Publications
- Top Cited Papers
- 1 September 2022
- Published by Elsevier in Ophthalmology
- Vol. 129 (10) , e114-e126
Improving Access to Eye Care
- 1 September 2022
- Published by Elsevier in Ophthalmology
- Vol. 129 (10) , e114-e126
Top Cited PapersImproving Access to Eye Care
- Open Access
- 1 January 2021
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 15, 3401-3417
Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study
Purpose: To report findings when dilated fundus examination (DFE) is omitted from follow-up of patients receiving anti-VEGF injections for neovascular age-related macular degeneration (NVAMD). Design: Randomized pilot study. Participants: NVAMD patients with two or more injections of anti-VEGF within prior six months who were expected to require treatment for at least eight more months. Methods and Interventions: Participants were assigned to either retinal imaging and DFE or retinal imaging without a DFE except at 16 weeks and 32 weeks and at study completion. Outcomes: Primary safety outcomes were change in usual-corrected visual acuity (UCVA) and central subfield thickness (CST). Primary efficacy outcomes included time spent in clinic and patient satisfaction with clinic visits. Results: The 66 participants had mean baseline UCVA of 20/50 in the study eye. Median change in UCVA from baseline to each clinic visit in each arm was "no change". Mean change in CST was less than 15 microns from baseline to any follow-up clinic visit. Time spent in the clinic at follow-up visits averaged 20 minutes less for participants in the Imaging Only group than those in the Full Exam group. More participants in the Imaging Only group were satisfied with the time spent in clinic and with the clinic visits overall than participants in the Full Exam group: means of 71 vs 91 minutes, respectively, per clinic visit. Conclusion: Based on findings from this randomized pilot study, follow-up retina clinic visits for established patients who have NVAMD and are under treatment with intravitreous injection of anti-VEGF agents could be streamlined by implementing longer intervals between DFE and by relying on imaging alone to make most decisions regarding the need for retreatment, thereby reducing the time spent by patients in clinic and increasing their satisfaction with care received, without excess adverse events.
- 1 January 2021
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 15, 3401-3417
Open AccessAre Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study
Purpose: To report findings when dilated fundus examination (DFE) is omitted from follow-up of patients receiving anti-VEGF injections for neovascular age-related macular degeneration (NVAMD). Design: Randomized pilot study. Participants: NVAMD patients with two or more injections of anti-VEGF within prior six months who were expected to require treatment for at least eight more months. Methods and Interventions: Participants were assigned to either retinal imaging and DFE or retinal imaging without a DFE except at 16 weeks and 32 weeks and at study completion. Outcomes: Primary safety outcomes were change in usual-corrected visual acuity (UCVA) and central subfield thickness (CST). Primary efficacy outcomes included time spent in clinic and patient satisfaction with clinic visits. Results: The 66 participants had mean baseline UCVA of 20/50 in the study eye. Median change in UCVA from baseline to each clinic visit in each arm was "no change". Mean change in CST was less than 15 microns from baseline to any follow-up clinic visit. Time spent in the clinic at follow-up visits averaged 20 minutes less for participants in the Imaging Only group than those in the Full Exam group. More participants in the Imaging Only group were satisfied with the time spent in clinic and with the clinic visits overall than participants in the Full Exam group: means of 71 vs 91 minutes, respectively, per clinic visit. Conclusion: Based on findings from this randomized pilot study, follow-up retina clinic visits for established patients who have NVAMD and are under treatment with intravitreous injection of anti-VEGF agents could be streamlined by implementing longer intervals between DFE and by relying on imaging alone to make most decisions regarding the need for retreatment, thereby reducing the time spent by patients in clinic and increasing their satisfaction with care received, without excess adverse events.
- Open Access
- 27 August 2019
- Published by S. Karger AG in Ophthalmic Research
- Vol. 62 (4) , 190-195
ETDRS Grading of Diabetic Retinopathy: Still the Gold Standard?
This article aims to provide a narrative history of the evolution, modification, and legacy of the Early Treatment Diabetic Retinopathy Study classification system.
- 27 August 2019
- Published by S. Karger AG in Ophthalmic Research
- Vol. 62 (4) , 190-195
Open AccessETDRS Grading of Diabetic Retinopathy: Still the Gold Standard?
This article aims to provide a narrative history of the evolution, modification, and legacy of the Early Treatment Diabetic Retinopathy Study classification system.
- Top Cited Papers
- 4 March 2019
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2019 (3) , CD005139
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
Background Age‐related macular degeneration (AMD) is the most common cause of uncorrectable severe vision loss in people aged 55 years and older in the developed world. Choroidal neovascularization (CNV) secondary to AMD accounts for most cases of AMD‐related severe vision loss. Intravitreous injection of anti‐vascular endothelial growth factor (anti‐VEGF) agents aims to block the growth of abnormal blood vessels in the eye to prevent vision loss and, in some instances, to improve vision. Objectives • To investigate ocular and systemic effects of, and quality of life associated with, intravitreous injection of three anti‐VEGF agents (pegaptanib, ranibizumab, and bevacizumab) versus no anti‐VEGF treatment for patients with neovascular AMD • To compare the relative effects of one of these anti‐VEGF agents versus another when administered in comparable dosages and regimens Search methods To identify eligible studies for this review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL), which contains the Cochrane Eyes and Vision Trials Register (searched January 31, 2018); MEDLINE Ovid (1946 to January 31, 2018); Embase Ovid (1947 to January 31, 2018); the Latin American and Caribbean Health Sciences Literature Database (LILACS) (1982 to January 31, 2018); the International Standard Randomized Controlled Trials Number (ISRCTN) Registry (www.isrctn.com/editAdvancedSearch ‐ searched January 31, 2018); ClinicalTrials.gov (www.clinicaltrials.gov ‐ searched November 28, 2018); and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en ‐ searched January 31, 2018). We did not impose any date or language restrictions in electronic searches for trials. Selection criteria We included randomized controlled trials (RCTs) that evaluated pegaptanib, ranibizumab, or bevacizumab versus each other or versus a control treatment (e.g. sham treatment, photodynamic therapy), in which participants were followed for at least one year. Data collection and analysis Two review authors independently screened records, extracted data, and assessed risks of bias. We contacted trial authors for additional data. We compared outcomes using risk ratios (RRs) or mean differences (MDs). We used the standard methodological procedures expected by Cochrane. Main results We included 16 RCTs that had enrolled a total of 6347 participants with neovascular AMD (the number of participants per trial ranged from 23 to 1208) and identified one potentially relevant ongoing trial. Six trials compared anti‐VEGF treatment (pegaptanib, ranibizumab, or bevacizumab) versus control, and 10 trials compared bevacizumab versus ranibizumab. Pharmaceutical companies conducted or sponsored four trials but funded none of the studies that evaluated bevacizumab. Researchers conducted these trials at various centers across five continents (North and South America, Europe, Asia, and Australia). The overall certainty of the evidence was moderate to high, and most trials had an overall low risk of bias. All but one trial had been registered prospectively. When compared with those who received control treatment, more participants who received intravitreous injection of any of the three anti‐VEGF agents had gained 15 letters or more of visual acuity (risk ratio [RR] 4.19, 95% confidence interval [CI] 2.32 to 7.55; moderate‐certainty evidence), had lost fewer than 15 letters of visual acuity (RR 1.40, 95% CI 1.27 to 1.55; high‐certainty evidence), and showed mean improvement in visual acuity (mean difference 6.7 letters, 95% CI 4.4 to 9.0 in one pegaptanib trial; mean difference 17.8 letters, 95% CI 16.0 to 19.7 in three ranibizumab trials; moderate‐certainty evidence) after one year of follow‐up. Participants treated with anti‐VEGF agents showed improvement in morphologic outcomes (e.g. size of CNV, central retinal thickness) compared with participants not treated with anti‐VEGF agents (moderate‐certainty evidence). No trial directly compared pegaptanib versus another anti‐VEGF agent and followed participants for one year; however, when compared with control treatments, ranibizumab and bevacizumab each yielded larger improvements in visual acuity outcomes than pegaptanib. Visual acuity outcomes after bevacizumab and ranibizumab were similar when the same RCTs compared the same regimens with respect to gain of 15 or more letters of visual acuity (RR 0.95, 95% CI 0.81 to 1.12; high‐certainty evidence) and loss of fewer than 15 letters of visual acuity (RR 1.00, 95% CI 0.98 to 1.02; high‐certainty evidence); results showed similar mean improvement in visual acuity (mean difference [MD] ‐0.5 letters, 95% CI ‐1.5 to 0.5; high‐certainty evidence) after one year of follow‐up, despite the substantially lower cost of bevacizumab compared with ranibizumab. Reduction in central retinal thickness was less among bevacizumab‐treated participants than among ranibizumab‐treated participants after one year (MD ‐11.6 μm, 95% CI ‐21.6 to ‐1.7; high‐certainty evidence); however, this difference is within the range of measurement error, and we did not interpret it to be clinically meaningful. Ocular inflammation and increased intraocular pressure (IOP) after intravitreal injection were the most frequently reported serious ocular adverse events. Researchers reported endophthalmitis in less than 1% of anti‐VEGF‐treated participants and in no cases among control groups. The occurrence of serious systemic adverse events was comparable across anti‐VEGF‐treated groups and control groups; however, the numbers of events and trial participants may have been insufficient to show a meaningful difference between groups (evidence of low‐ to moderate‐certainty)....
- 4 March 2019
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2019 (3) , CD005139
Top Cited PapersAnti-vascular endothelial growth factor for neovascular age-related macular degeneration
Background Age‐related macular degeneration (AMD) is the most common cause of uncorrectable severe vision loss in people aged 55 years and older in the developed world. Choroidal neovascularization (CNV) secondary to AMD accounts for most cases of AMD‐related severe vision loss. Intravitreous injection of anti‐vascular endothelial growth factor (anti‐VEGF) agents aims to block the growth of abnormal blood vessels in the eye to prevent vision loss and, in some instances, to improve vision. Objectives • To investigate ocular and systemic effects of, and quality of life associated with, intravitreous injection of three anti‐VEGF agents (pegaptanib, ranibizumab, and bevacizumab) versus no anti‐VEGF treatment for patients with neovascular AMD • To compare the relative effects of one of these anti‐VEGF agents versus another when administered in comparable dosages and regimens Search methods To identify eligible studies for this review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL), which contains the Cochrane Eyes and Vision Trials Register (searched January 31, 2018); MEDLINE Ovid (1946 to January 31, 2018); Embase Ovid (1947 to January 31, 2018); the Latin American and Caribbean Health Sciences Literature Database (LILACS) (1982 to January 31, 2018); the International Standard Randomized Controlled Trials Number (ISRCTN) Registry (www.isrctn.com/editAdvancedSearch ‐ searched January 31, 2018); ClinicalTrials.gov (www.clinicaltrials.gov ‐ searched November 28, 2018); and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en ‐ searched January 31, 2018). We did not impose any date or language restrictions in electronic searches for trials. Selection criteria We included randomized controlled trials (RCTs) that evaluated pegaptanib, ranibizumab, or bevacizumab versus each other or versus a control treatment (e.g. sham treatment, photodynamic therapy), in which participants were followed for at least one year. Data collection and analysis Two review authors independently screened records, extracted data, and assessed risks of bias. We contacted trial authors for additional data. We compared outcomes using risk ratios (RRs) or mean differences (MDs). We used the standard methodological procedures expected by Cochrane. Main results We included 16 RCTs that had enrolled a total of 6347 participants with neovascular AMD (the number of participants per trial ranged from 23 to 1208) and identified one potentially relevant ongoing trial. Six trials compared anti‐VEGF treatment (pegaptanib, ranibizumab, or bevacizumab) versus control, and 10 trials compared bevacizumab versus ranibizumab. Pharmaceutical companies conducted or sponsored four trials but funded none of the studies that evaluated bevacizumab. Researchers conducted these trials at various centers across five continents (North and South America, Europe, Asia, and Australia). The overall certainty of the evidence was moderate to high, and most trials had an overall low risk of bias. All but one trial had been registered prospectively. When compared with those who received control treatment, more participants who received intravitreous injection of any of the three anti‐VEGF agents had gained 15 letters or more of visual acuity (risk ratio [RR] 4.19, 95% confidence interval [CI] 2.32 to 7.55; moderate‐certainty evidence), had lost fewer than 15 letters of visual acuity (RR 1.40, 95% CI 1.27 to 1.55; high‐certainty evidence), and showed mean improvement in visual acuity (mean difference 6.7 letters, 95% CI 4.4 to 9.0 in one pegaptanib trial; mean difference 17.8 letters, 95% CI 16.0 to 19.7 in three ranibizumab trials; moderate‐certainty evidence) after one year of follow‐up. Participants treated with anti‐VEGF agents showed improvement in morphologic outcomes (e.g. size of CNV, central retinal thickness) compared with participants not treated with anti‐VEGF agents (moderate‐certainty evidence). No trial directly compared pegaptanib versus another anti‐VEGF agent and followed participants for one year; however, when compared with control treatments, ranibizumab and bevacizumab each yielded larger improvements in visual acuity outcomes than pegaptanib. Visual acuity outcomes after bevacizumab and ranibizumab were similar when the same RCTs compared the same regimens with respect to gain of 15 or more letters of visual acuity (RR 0.95, 95% CI 0.81 to 1.12; high‐certainty evidence) and loss of fewer than 15 letters of visual acuity (RR 1.00, 95% CI 0.98 to 1.02; high‐certainty evidence); results showed similar mean improvement in visual acuity (mean difference [MD] ‐0.5 letters, 95% CI ‐1.5 to 0.5; high‐certainty evidence) after one year of follow‐up, despite the substantially lower cost of bevacizumab compared with ranibizumab. Reduction in central retinal thickness was less among bevacizumab‐treated participants than among ranibizumab‐treated participants after one year (MD ‐11.6 μm, 95% CI ‐21.6 to ‐1.7; high‐certainty evidence); however, this difference is within the range of measurement error, and we did not interpret it to be clinically meaningful. Ocular inflammation and increased intraocular pressure (IOP) after intravitreal injection were the most frequently reported serious ocular adverse events. Researchers reported endophthalmitis in less than 1% of anti‐VEGF‐treated participants and in no cases among control groups. The occurrence of serious systemic adverse events was comparable across anti‐VEGF‐treated groups and control groups; however, the numbers of events and trial participants may have been insufficient to show a meaningful difference between groups (evidence of low‐ to moderate‐certainty)....
- 1 November 2018
- Published by Elsevier in Ophthalmology Retina
- Vol. 2 (11) , 1085-1086
Systemic Safety of Ranibizumab for Neovascular Age-Related Macular Degeneration: Do Ophthalmologists Still Have to Sweat the Small Stuff?
- 1 November 2018
- Published by Elsevier in Ophthalmology Retina
- Vol. 2 (11) , 1085-1086
Systemic Safety of Ranibizumab for Neovascular Age-Related Macular Degeneration: Do Ophthalmologists Still Have to Sweat the Small Stuff?
- 1 January 2018
- Published by Elsevier in Medical Image Analysis
- Vol. 43, 85-97
Intensity inhomogeneity correction of SD-OCT data using macular flatspace
- 1 January 2018
- Published by Elsevier in Medical Image Analysis
- Vol. 43, 85-97
Intensity inhomogeneity correction of SD-OCT data using macular flatspace
- Open Access
- 15 November 2017
- Published by Springer Nature in Clinical Proteomics
- Vol. 14 (1) , 37
A proteomic approach to understanding the pathogenesis of idiopathic macular hole formation
Idiopathic macular holes (IMH) are full-thickness defects of retinal tissue that cause severe vision loss due to disruption of the anatomic fovea. Abnormal vitreous traction is involved in the formation of macular holes. Both glial cells and hyalocytes contribute to epiretinal membrane formation in IMH. In order to gain further insight into the pathophysiology of IMH, we conducted a discovery phase investigation of the vitreous proteome in four patients with macular holes and six controls using one-dimensional gel fractionation and liquid chromatography–tandem mass spectrometry analyses on an Orbitrap Elite mass spectrometer. Of a total of 5912 vitreous proteins, 32 proteins had increased and 39 proteins had decreased expression in IMH compared with controls, using a false discovery rate approach with p value < 0.001 and q value < 0.05. IMH was associated with increased expression of proteins in the complement pathway, α-2-macroglobulin, a major inducer of Müller glial cell migration, fibrinogen, and extracellular matrix proteins, and decreased expression of proteins involved in protein folding and actin filament binding. A proteomic approach revealed proteins and biological pathways that may be involved in the pathogenesis of IMH and could be targeted for future studies.
- 15 November 2017
- Published by Springer Nature in Clinical Proteomics
- Vol. 14 (1) , 37
Open AccessA proteomic approach to understanding the pathogenesis of idiopathic macular hole formation
Idiopathic macular holes (IMH) are full-thickness defects of retinal tissue that cause severe vision loss due to disruption of the anatomic fovea. Abnormal vitreous traction is involved in the formation of macular holes. Both glial cells and hyalocytes contribute to epiretinal membrane formation in IMH. In order to gain further insight into the pathophysiology of IMH, we conducted a discovery phase investigation of the vitreous proteome in four patients with macular holes and six controls using one-dimensional gel fractionation and liquid chromatography–tandem mass spectrometry analyses on an Orbitrap Elite mass spectrometer. Of a total of 5912 vitreous proteins, 32 proteins had increased and 39 proteins had decreased expression in IMH compared with controls, using a false discovery rate approach with p value < 0.001 and q value < 0.05. IMH was associated with increased expression of proteins in the complement pathway, α-2-macroglobulin, a major inducer of Müller glial cell migration, fibrinogen, and extracellular matrix proteins, and decreased expression of proteins involved in protein folding and actin filament binding. A proteomic approach revealed proteins and biological pathways that may be involved in the pathogenesis of IMH and could be targeted for future studies.
- 1 October 2016
- Published by Elsevier in Ophthalmology
- Vol. 123 (10) , S61
Great Advances in Retina: Past, Present, and Future
- 1 October 2016
- Published by Elsevier in Ophthalmology
- Vol. 123 (10) , S61
Great Advances in Retina: Past, Present, and Future
- Open Access
- 30 January 2015
- Published by Springer Nature in BMC Ophthalmology
- Vol. 15 (1) , 9
Evaluation of real-world mobility in age-related macular degeneration
Previous research has suggested an association between poor vision and decreased mobility, including restricted levels of physical activity and travel away from home. We sought to determine the impact of age-related macular degeneration (AMD) on these measures of mobility.
- 30 January 2015
- Published by Springer Nature in BMC Ophthalmology
- Vol. 15 (1) , 9
Open AccessEvaluation of real-world mobility in age-related macular degeneration
Previous research has suggested an association between poor vision and decreased mobility, including restricted levels of physical activity and travel away from home. We sought to determine the impact of age-related macular degeneration (AMD) on these measures of mobility.